pH-Dependent Adenosine Agonists for Pain

The patent applies the local quality principle by designing adenosine receptor agonists with pH-dependent affinity characteristics. The compounds exhibit high affinity for adenosine receptors specifically in acidic environments (pathological tissues with pH below 7.4) while having low affinity in normal physiological conditions (pH 7.4). This spatial differentiation of binding affinity allows selective action at disease sites without activating receptors in healthy tissues, thereby achieving therapeutic effects while minimizing systemic side effects such as hypotension and tachycardia.

The patent implements parameter changes by modifying the chemical structure of adenosine receptor agonists to introduce pH-dependent binding properties. The compounds contain specific molecular features that cause their receptor affinity to vary with pH levels. In acidic environments (pH < 7.4) characteristic of inflamed or pathological tissues, the compounds maintain high affinity and activate receptors effectively. In contrast, at normal physiological pH (7.4), their affinity drops significantly, preventing activation of adenosine receptors in healthy tissues and avoiding associated side effects.

The patent applies local quality by creating A2A receptor agonists that selectively bind to adenosine receptors in acidic environments. The compounds maintain high affinity for A2A receptors specifically in inflamed tissues where pH is reduced, enabling localized anti-inflammatory action. In normal tissues with physiological pH, the compounds have minimal affinity and do not activate receptors, thereby avoiding the vasodilation and hypotension that result from widespread A2A receptor activation throughout the body.

The patent utilizes parameter changes by designing A2A receptor agonists with pH-dependent binding affinity. The molecular structure is optimized so that receptor activation occurs only when the local pH drops below 7.4, as occurs in inflammatory conditions. This pH-gated mechanism ensures that anti-inflammatory effects are confined to pathological sites while preventing the systemic vasodilation and hypotension that would result from broad receptor activation in healthy vasculature.

The patent applies local quality by developing analgesic compounds that selectively target acidic environments where pain and inflammation occur. The pH-dependent affinity ensures that even at low systemic doses, the compounds concentrate their activity in pathological tissues with reduced pH, providing effective pain relief. Meanwhile, healthy tissues with normal pH remain unaffected, preventing dose-dependent side effects that would otherwise limit therapeutic dosing.

The patent implements parameter changes by creating analgesics with pH-dependent receptor binding characteristics. This molecular design allows the compounds to maintain high affinity and potency specifically in the acidic microenvironment of inflamed or damaged tissues, enabling effective pain control at low doses. In contrast, in normal physiological conditions, the compounds exhibit minimal activity, thereby avoiding the side effects that typically increase with higher dosing regimens.